Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first licensed therapy to utilise CRISPR/Cas9 gene-editing technology, whose inventors were awarded the 2020 Nobel Prize in Chemistry. The therapy offers a potential functional cure for SCD and transfusion-dependent beta-thalassaemia (TDT)—inherited blood disorders that significantly impact health and life expectancy.
This achievement follows Bahrain's landmark decision on 2 December 2023 to become the second country globally and the first in the Middle East to approve Casgevy for the treatment of SCD and TDT. The approval was granted after a rigorous evaluation of the therapy's safety, quality, and efficacy.
The multi-stage transplant process involves stimulating the patient's bone marrow to produce large quantities of stem cells using specialised injections, then editing the stem cells to produce red blood cells carrying functional haemoglobin. The third and final stage is transplanting the edited cells back into the patient's bloodstream after rigorous quality and safety testing. This process can be used to treat Thalassaemia (Mediterranean anaemia).
HE. Dr. Jaleela bint AlSayed Jawad Hasan, Minister of Health, said: 'This milestone exemplifies Bahrain's commitment to integrating global medical innovations into our national healthcare strategy. By fostering partnerships across institutions, we are delivering on our mandate to provide access to life-changing therapies for all beneficiaries and positioning Bahrain as a hub for innovative medical care, in line with the visionary directives of His Majesty King Hamad bin Isa Al Khalifa and His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister.'
'Bahrain is proud to be at the forefront of cutting-edge healthcare advancements in the region. The successful administration of Gene edited autologous stem cell transplant demonstrates our dedication to providing access the most advanced treatments and reinforces our position as a regional hub for precision medicine,' said Brigadier Dr. Shaikh Fahad bin Khalifa bin Salman Al Khalifa, Commander of the RMS. 'This provides renewed hope for patients with complex blood disorders and reinforces the Kingdom's growing focus on healthcare innovation.'
'As the clinical team responsible for delivering this groundbreaking treatment, we are honoured to bring CRISPR-based therapy to patients in Bahrain and beyond. Our success reflects the Bahrain Oncology Centre's dedication to combining advanced technology with world-class expertise. This achievement, validated by our international accreditation in bone marrow transplantation, underscores our mission to transform patient outcomes through precision medicine and collaboration with global pioneers,' said Dr Edward Rowland, CEO of Bahrain Oncology Centre.
The introduction of gene-edited autologous stem cell transplant aligns with Bahrain's national healthcare strategy, which focuses on fostering global partnerships, driving medical innovation, and ensuring access to state-of-the-art technologies. This strategy reflects the vision of His Majesty King Hamad bin Isa Al Khalifa and the directives of His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, to provide world-class, innovative healthcare.
The success of this programme is the result of collaboration between the Ministry of Health, the Royal Medical Services, Government Hospitals, and the National Health Regulatory Authority, reinforcing Bahrain's role as a regional leader in advanced healthcare solutions.
About Bahrain Oncology Centre
The Bahrain Oncology Centre (BOC) is a leading provider of comprehensive oncology services in the Kingdom, including bone marrow transplantation. Committed to delivering world-class healthcare, BOC integrates cutting-edge medical technologies with a multidisciplinary approach to improve patient outcomes. In 2024, BOC received Vertex accreditation for its bone marrow transplant and cellular therapy services, enabling it to provide, as an accredited centre of excellence, CRISPR-based gene-editing therapy, Casgevy (exagamglogene autotemcel), to sickle cell disorder and beta thalassaemia patients from all over the globe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
4 hours ago
- Toronto Star
BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic's IzoView Device
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) — via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ('Izotropic', or the 'Company'), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of a new online platform supporting the Company's awareness initiatives. has been created as a central educational resource on dedicated breast CT technology and the Company's IzoView Breast CT Imaging System, with a focus on its potential to address persistent challenges in detecting breast cancer in the 50% of women with dense breast tissue. With IzoView's engineering complete, the site is designed to evolve alongside the Company through clinical study preparation, U.S. and global regulatory phases, and ongoing education and awareness initiatives leading to commercial launch.
Calgary Herald
4 hours ago
- Calgary Herald
Welcome to Vitality Alberta: Work Well
Article content Organizations with visionary leadership know this. At Alberta Blue Cross, we're fortunate to work alongside many such Alberta-based organizations that lead from a position of strength and invest in well-being before a crisis hits. Article content But there's a gap. According to our Creating a high performing work force: The importance of a well-being strategy report from earlier this year, 90 per cent of the organizations know how crucial employee well-being is to their overall talent value proposition. Yet half still don't have a strategy. Article content To be fair, employers don't need all the answers right away. What they do need is the courage to act and the willingness to learn. Article content That brings me to this exciting partnership with Postmedia for the Vitality Alberta: Work Well series. The series will explore topics like using technology to support personalized wellness, managing stress, building flexibility into the workplace and more. It's a meaningful starting point and will offer practical articles focused on strengthening workplace well-being. Article content Well-being at work isn't a checkbox. It's a culture. It's how we lead, how we listen and how we build workplaces that truly respect people and their lives. When we commit to that, we're helping build a brighter future for all Albertans.
Cision Canada
5 hours ago
- Cision Canada
Doseology Acquires Feed That Brain™ and Appoints Joseph Mimran as Strategic Advisor
KELOWNA, BC, Aug. 19, 2025 /CNW/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company"), an innovator in precision-formulated oral stimulants, is pleased to announce that it has entered into an asset purchase and sale agreement (the "Asset Purchase Agreement") to acquire the 'Feed That Brain' division (the "FTB Assets") operated by Joseph Mimran & Associates Inc. (the "Vendor") for aggregate consideration of $400,000 (the "Purchase Price") (the "Transaction"). The Purchase Price will be satisfied through the issuance of securities of the Company (the "Consideration Securities"), which will be issued in four instalments (common shares valued at $175,000 on the closing date and a further $75,000 of pre-funded warrants every six (6) months thereafter) at a deemed price equal to the greater of (i) $1.00 per Consideration Security, or (ii) the lowest price permitted under the applicable policies of the Canadian Securities Exchange. The initial instalment of 175,000 common shares at a price of $1.00 per share will be issued upon closing. FTB Brand Vision and Strategic Fit Founded by Rena R. Dempsey—a Forbes-recognized wellness entrepreneur with 20+ years in nutraceutical, beauty, and health product innovation, Feed That Brain™ (FTB) is a Toronto-based health supplements division operated by the Vendor, specializing in cognitive performance, wellness, and beauty from within. The established brand equity of the FTB Assets is expected to help Doseology accelerate its Canadian launch of next-generation clean energy pouches, positioning the Company not just as a tobacco alternative but as an extension of our already trusted performance wellness platform. The FTB Assets include all of FTB's business plan, inventory, contracts, material agreements, purchase orders, distribution agreements, intangible property, know-how, goodwill and other related assets, including all rights to the exclusive use of the branding of the 'Feed That Brain' business including web assets and systems and physical and digital elements. The Transaction remains subject to regulatory approval and customary closing conditions. The Consideration Shares to be issued to the Vendor will be subject to a four-month hold period in accordance with Securities Laws in Canada. Mimran Joins as Strategic Advisor Doseology welcomes Joseph Mimran as a strategic advisor, as Mr. Mimran has agreed to enter into a three (3) year strategic advisory agreement with the Company (the "Advisory Agreement") upon closing, pursuant to which he will be bringing his unmatched expertise in brand development, retail strategy, and investment to the Company. His guidance is expected to be instrumental in supporting Doseology's execution roadmap, with the goal of establishing the Company as a category-defining force in both clean energy and harm reduction pouches. Pursuant to the Advisory Agreement, the Company has agreed to grant the Mr. Mimran restricted share units (the "RSUs") of the Company valued at $400,000. The RSUs will be issued every six (6) months from the closing date of the Transaction in equal instalments of $66,666 over a period of three (3) years and priced at the market price of the Company's common shares at the time of each issuance. Mr. Mimran's deep experience in brand building is complemented by a proven M&A track record through his family office. He has led the acquisition and revitalization of brands like Mastermind Toys, Kit and Ace, Tilley, and Coco Village—bringing strategic foresight and operational discipline to both heritage and emerging businesses. He is also the creator of notable brands such as Gry Mattr and Rise Little Earthling and has a history of building category-defining concepts from the ground up. Doseology's growth model includes targeted M&A, IP sourcing, and licensing of disruptive wellness formats—anchored in science and brand scalability. This is especially relevant in the clean energy and nicotine harm reduction sectors, where demand for functionally optimized, accessible, and clean delivery formats is accelerating. This alignment of vision and execution makes Mr. Mimran's advisory appointment a foundational step as Doseology builds a best-in-class team of experts from consumer products, Big Tobacco, and institutional finance. "Doseology is building something both innovative and timely," said Mimran. "I'm excited to work alongside the team in shaping a brand that redefines how energy and performance can be delivered." The Rise of Pouches in Clean Energy & Harm Reduction Oral Stimulant pouches mark Doseology's entry into two high-growth markets: Consumers are increasingly seeking portable, clean, crash-free formats for focus, alertness, and productivity; especially, among working professionals, athletes, military personnel, and high-output individuals. Pouches offer a convenient, sugar-free alternative to traditional beverages—perfectly aligned with modern performance lifestyles. Source 2: ( About Joseph Mimran & Associates Inc. Joseph Mimran is a Canadian designer, entrepreneur, and retail visionary with a 40+ year track record of building billion-dollar consumer brands. He co-founded the Alfred Sung brand and founded Club Monaco, later acquired by Ralph Lauren. He is also the founder of Joe Fresh, one of Canada's most successful apparel brands. Through his firm, Joseph Mimran & Associates, he advises high-growth companies on design, retail strategy, and brand development. He is the owner of Tilley Endurables, Gry Mattr, Rise Little Earthling, and Coco Village, as well as the majority shareholder of Mastermind Toys and Kit and Ace. His work spans apparel, home, lifestyle, and toy categories, with a unique ability to combine creative vision and disciplined execution. Mimran's career also includes serving as a Dragon on CBC's Dragons' Den from 2015 to 2018, where he championed Canadian entrepreneurship. About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) Doseology is a biotech innovation company, engineering precision‑formulated oral stimulants that optimize energy, focus, and cognitive performance. Through rigorous scientific research and advanced delivery technologies, we're pioneering next‑gen performance solutions designed to empower peak performance. On behalf of the Board of Directors, Chris Jackson CEO Doseology Sciences Inc. For more information, please contact the Company at: Email: [email protected] Website: Phone: 604.908.3095 Forward Looking Statements This press release contains statements that constitute "forward‐looking information" within the meaning of applicable securities laws. Forward‐looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR+. No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company's securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The CSE does not accept responsibility for the adequacy or accuracy of this release.
